Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BRUKER CORPBRKR · Entity 3609 | Director | February 15, 2026 | February 18, 2026 |
| SI-BONE, Inc.SIBN · Entity 2501 | Director · Chief Executive Officer | October 12, 2026 | October 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BRUKER CORP
Report date February 15, 2026 · Filed February 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,018 |
Reported balance
After 2026-02-15 transaction · row 1
1 source rowRow 1 · 2026-02-15 · Grant · Acquired 4,520 · Balance 9,018 F1: This grant is represented by Restricted Stock Units (RSU) and will vest in one installment on February 15, 2027. On the vesting date, each RSU will automatically convert into a similar number of shares of Common Stock. |
Filing footnotes · ownership attribution and instrument terms
F1: This grant is represented by Restricted Stock Units (RSU) and will vest in one installment on February 15, 2027. On the vesting date, each RSU will automatically convert into a similar number of shares of Common Stock.
SI-BONE, Inc.
Report date October 12, 2026 · Filed October 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Indirectby Trust | 379,256 |
Reported balance
After 2026-10-12 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-10-12 · Sale · Disposed 38,006 · Balance 379,256 F1: The sale reported on this Form 4 was effected pursuant to a 10b5-1 trading plan dated May 21, 2026. F2: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $20.00 to $20.1050, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. F3: Reflects the transfer of shares from the Reporting Person to The David & Laura Joint Rev Tr. F4: Shares held by The David & Laura Joint Rev Tr. |
| Common StockSEC Table I · non-derivative | Direct | 368,129 |
Reported balance
Holding disclosure · report date 2026-10-12 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 368,129 F5: Includes 355,697 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported on this Form 4 was effected pursuant to a 10b5-1 trading plan dated May 21, 2026.
F2: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $20.00 to $20.1050, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes.
F3: Reflects the transfer of shares from the Reporting Person to The David & Laura Joint Rev Tr.
F4: Shares held by The David & Laura Joint Rev Tr.
F5: Includes 355,697 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Shockwave Medical, Inc.
Report date May 31, 2024 · Filed May 31, 2024
Section 16 reporting ended · disclosed 2024-05-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-05-31 transaction · row 1
1 source rowRow 1 · 2024-05-31 · Disposition to issuer · Disposed 1,233 · Balance 0 F1: This Form 4 reports the disposition of securities pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 4, 2024, by and among the Issuer, Johnson & Johnson ("J&J"), and Sweep Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of the effective time of the Merger (the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. As a result of the Merger, at the Effective Time, each outstanding share of common stock, par value $0.001 per share, of the Issuer ("Common Stock") outstanding immediately prior to the Effective Time (excluding Excluded Shares and any Dissenting Company Shares, each as defined in the Merger Agreement) was automatically converted into the right to receive $335.00 in cash (the "Merger Consideration"), F2: (Continued from Footnote 1) without interest and less any applicable withholding taxes. Additionally, pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time and (ii) the Merger Consideration. |
| Common StockSEC Table I · non-derivative | IndirectDavid and Laura Francis Joint Rev Trust | 0 |
Reported balance
After 2024-05-31 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2024-05-31 · Disposition to issuer · Disposed 3,551 · Balance 0 F1: This Form 4 reports the disposition of securities pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 4, 2024, by and among the Issuer, Johnson & Johnson ("J&J"), and Sweep Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of the effective time of the Merger (the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. As a result of the Merger, at the Effective Time, each outstanding share of common stock, par value $0.001 per share, of the Issuer ("Common Stock") outstanding immediately prior to the Effective Time (excluding Excluded Shares and any Dissenting Company Shares, each as defined in the Merger Agreement) was automatically converted into the right to receive $335.00 in cash (the "Merger Consideration"), F2: (Continued from Footnote 1) without interest and less any applicable withholding taxes. Additionally, pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time and (ii) the Merger Consideration. F3: These shares are held in a trust for the benefit of the reporting person's children. The reporting person and the reporting person's spouse are trustees of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $6.59 · Expires 2029-02-01 | Direct | 0 |
Reported balance
After 2024-05-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-05-31 · Disposition to issuer · Disposed 13,690 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price that was less than the Merger Consideration, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports the disposition of securities pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of April 4, 2024, by and among the Issuer, Johnson & Johnson ("J&J"), and Sweep Merger Sub, Inc., a wholly owned subsidiary of J&J ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of the effective time of the Merger (the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of J&J. As a result of the Merger, at the Effective Time, each outstanding share of common stock, par value $0.001 per share, of the Issuer ("Common Stock") outstanding immediately prior to the Effective Time (excluding Excluded Shares and any Dissenting Company Shares, each as defined in the Merger Agreement) was automatically converted into the right to receive $335.00 in cash (the "Merger Consideration"),
F2: (Continued from Footnote 1) without interest and less any applicable withholding taxes. Additionally, pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such RSU immediately prior to the Effective Time and (ii) the Merger Consideration.
F3: These shares are held in a trust for the benefit of the reporting person's children. The reporting person and the reporting person's spouse are trustees of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F4: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested, with a per share exercise price that was less than the Merger Consideration, was cancelled and converted into the right to receive a cash amount, without interest and less any applicable withholding taxes, equal to the product of (i) the aggregate number of shares of Common Stock underlying such Company Option immediately prior to the Effective Time, and (ii) the excess of (A) the Merger Consideration over (B) the per share exercise price of such Company Option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 29, 2022 Filed Mar 31, 2022 22:21 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 659 | $195.03 | $128,524.77 |
DisclosureSEC source: 0001209191-22-021842 · doc4.xml · nonDerivative · entry 7 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David and Laura Francis Joint Rev Trust Disclosed balance after: 1,211 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the David and Laura Francis Joint Revocable Trust on 2/27/2022. F7 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $194.45 to $195.43. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting persons children. The reporting persons spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 29, 2022 Filed Mar 31, 2022 22:21 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 180 | $193.93 | $34,907.40 |
DisclosureSEC source: 0001209191-22-021842 · doc4.xml · nonDerivative · entry 6 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David and Laura Francis Joint Rev Trust Disclosed balance after: 1,870 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the David and Laura Francis Joint Revocable Trust on 2/27/2022. F6 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $193.39 to $194.35. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting persons children. The reporting persons spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 29, 2022 Filed Mar 31, 2022 22:21 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 160 | $192.32 | $30,771.20 |
DisclosureSEC source: 0001209191-22-021842 · doc4.xml · nonDerivative · entry 5 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David and Laura Francis Joint Rev Trust Disclosed balance after: 2,050 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the David and Laura Francis Joint Revocable Trust on 2/27/2022. F5 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $191.91 to $192.80. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting persons children. The reporting persons spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 29, 2022 Filed Mar 31, 2022 22:21 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 100 | $190.37 | $19,037.00 |
DisclosureSEC source: 0001209191-22-021842 · doc4.xml · nonDerivative · entry 4 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David and Laura Francis Joint Rev Trust Disclosed balance after: 2,210 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the David and Laura Francis Joint Revocable Trust on 2/27/2022. F4 · price: The price reported in Column 4 is a weighted average price. The reported securities were sold in multiple transactions at prices ranging from $189.99 to $190.65. The reporting person undertakes to provide to the issuer, any security holder of the issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range. F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting persons children. The reporting persons spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 29, 2022 Filed Mar 31, 2022 22:21 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | GiftCommon Stock | 2,310 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-021842 · doc4.xml · nonDerivative · entry 3 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David and Laura Francis Joint Rev Trust Disclosed balance after: 2,310 F2 · kind: Represents a bona fide gift of securities by the reporting person to the David and Laura Francis Joint Revocable Trust in an exempt transaction pursuant to Rule 16b-5. The reporting person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein. F3 · ownership.nature: These shares are held in a trust for the benefit of the reporting persons children. The reporting persons spouse is trustee of the trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. Read SEC document |
| March 29, 2022 Filed Mar 31, 2022 22:21 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | GiftCommon Stock | 2,310 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-021842 · doc4.xml · nonDerivative · entry 2 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,551 F2 · kind: Represents a bona fide gift of securities by the reporting person to the David and Laura Francis Joint Revocable Trust in an exempt transaction pursuant to Rule 16b-5. The reporting person disclaims beneficial ownership of the reported securities except to the extent of her pecuniary interest therein. Read SEC document |
| March 29, 2022 Filed Mar 31, 2022 22:21 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionCommon Stock | 2,310 | $6.59 | $15,222.90 |
DisclosureSEC source: 0001209191-22-021842 · doc4.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,861 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the David and Laura Francis Joint Revocable Trust on 2/27/2022. Read SEC document |
| February 16, 2022 Filed Feb 17, 2022 19:46 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,050 | $20.38 | $21,402.78 |
DisclosureSEC source: 0001562180-22-001545 · primarydocument.xml · nonDerivative · entry 5 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,066 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 233,402 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 16, 2022 Filed Feb 17, 2022 19:46 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 712 | $20.38 | $14,513.12 |
DisclosureSEC source: 0001562180-22-001545 · primarydocument.xml · nonDerivative · entry 4 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,116 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 16, 2022 Filed Feb 17, 2022 19:46 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 433 | $20.38 | $8,826.10 |
DisclosureSEC source: 0001562180-22-001545 · primarydocument.xml · nonDerivative · entry 3 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,828 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 16, 2022 Filed Feb 17, 2022 19:46 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,442 | $20.38 | $29,393.15 |
DisclosureSEC source: 0001562180-22-001545 · primarydocument.xml · nonDerivative · entry 2 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,261 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 16, 2022 Filed Feb 17, 2022 19:46 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,140 | $20.38 | $23,237.30 |
DisclosureSEC source: 0001562180-22-001545 · primarydocument.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 338,703 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| January 07, 2022 Filed Jan 10, 2022 20:06 UTC | SI-BONE, Inc. SIBN · Entity 2501 | GrantCommon Stock | 63,864 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-000363 · primarydocument.xml · nonDerivative · entry 2 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,843 F2 · shares: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted unit represents a contingent right to receive one share of the Issuer's common stock. The shares are subjected to the restricted stock unit vest, if at all, over three years based on the Issuer's total shareholder return (TSR) as measured against the TSR of the company at the median of the range TSRs of a set of peer companies established by the Issuer as set forth in the grant. F3 · balance_after: Includes 247,439 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 07, 2022 Filed Jan 10, 2022 20:06 UTC | SI-BONE, Inc. SIBN · Entity 2501 | GrantCommon Stock | 63,865 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-000363 · primarydocument.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,979 F1 · shares: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will vest over four years beginning on January 1, 2022, and will be released in quarterly installments commencing on May 15, 2022, subject to the Reporting Person's continued service through each relevant vesting date. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 01:51 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,678 | $21.47 | $36,026.16 |
DisclosureSEC source: 0001562180-21-007145 · primarydocument.xml · nonDerivative · entry 4 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,114 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 119,710 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 01:51 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,530 | $21.47 | $32,848.64 |
DisclosureSEC source: 0001562180-21-007145 · primarydocument.xml · nonDerivative · entry 3 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,792 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 01:51 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 621 | $21.47 | $13,332.68 |
DisclosureSEC source: 0001562180-21-007145 · primarydocument.xml · nonDerivative · entry 2 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,322 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| November 16, 2021 Filed Nov 18, 2021 01:51 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,020 | $21.47 | $21,899.09 |
DisclosureSEC source: 0001562180-21-007145 · primarydocument.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,943 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| October 25, 2021 Filed Nov 18, 2021 01:51 UTC | SI-BONE, Inc. SIBN · Entity 2501 | GiftStock Options (Right to buy) · Derivative | 20,328 | $0.00 Strike: $22.00 | $0.00 |
DisclosureSEC source: 0001562180-21-007145 · primarydocument.xml · derivative · entry 5 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,437 Underlying: Common Stock · 20,238 shares Expires 2029-01-15 F3 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over four years commencing on vesting commencement date, subject to Reporting Person's continued service through each relevant vesting date. F4 · balance_after: The reported transaction involves the Reporting Person's transfer of options to trusts for the benefit of Reporting Person's children. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 00:11 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,020 | $20.46 | $20,871.34 |
DisclosureSEC source: 0001562180-21-005331 · primarydocument.xml · nonDerivative · entry 5 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,963 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 129,472 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 00:11 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 621 | $20.46 | $12,706.96 |
DisclosureSEC source: 0001562180-21-005331 · primarydocument.xml · nonDerivative · entry 4 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,983 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 00:11 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,530 | $20.46 | $31,307.01 |
DisclosureSEC source: 0001562180-21-005331 · primarydocument.xml · nonDerivative · entry 3 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,604 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| August 16, 2021 Filed Aug 17, 2021 00:11 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,678 | $20.46 | $34,335.40 |
DisclosureSEC source: 0001562180-21-005331 · primarydocument.xml · nonDerivative · entry 2 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,134 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| August 12, 2021 Filed Aug 17, 2021 00:11 UTC | SI-BONE, Inc. SIBN · Entity 2501 | Exercise / conversionStock Option (Right to Buy) · Derivative | 13,635 | $0.00 Strike: $22.00 | $0.00 |
DisclosureSEC source: 0001562180-21-005331 · primarydocument.xml · derivative · entry 6 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,765 Underlying: Common Stock · 13,635 shares Expires 2029-01-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over four years commencing on vesting commencement date, subject to Reporting Person's continued service through each relevant vesting date. Read SEC document |
| August 12, 2021 Filed Aug 17, 2021 00:11 UTC | SI-BONE, Inc. SIBN · Entity 2501 | Exercise / conversionCommon Stock | 13,635 | $22.00 | $299,970.00 |
DisclosureSEC source: 0001562180-21-005331 · primarydocument.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 221,812 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 28, 2021 Filed Jul 10, 2021 01:40 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | GrantCommon Stock | 850 | $0.00 | $0.00 |
DisclosureSEC source: 0000950103-21-010316 · dp154196_4-francis.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,551 F1 · shares: Reflects shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The shares subject to the restricted stock units vest on 6/25/2022, subject to the Reporting Person's continued service through such date. Read SEC document |
| June 25, 2021 Filed Jul 14, 2022 23:37 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | GiftCommon Stock | 2,701 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-042197 · doc5.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 850 F1 · shares: On June 25, 2021, the reporting person transferred 2,701 shares of the issuer's common stock to a family trust of which the reporting person is trustee. The reporting person and members of her immediate family are the sole beneficiaries of the trust. Read SEC document |
| June 24, 2021 Filed Jun 25, 2021 22:15 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $6.59 | $0.00 |
DisclosureSEC source: 0000950103-21-009417 · dp153299_4-francis.xml · derivative · entry 4 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,390 Underlying: Common Stock · 1,500 shares Expires 2029-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 5/14/2021. F2 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest monthly from 1/3/19. Read SEC document |
| June 24, 2021 Filed Jun 25, 2021 22:15 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 1,500 | $200.00 | $300,000.00 |
DisclosureSEC source: 0000950103-21-009417 · dp153299_4-francis.xml · nonDerivative · entry 2 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David and Laura Francis Joint Rev Trust Disclosed balance after: 0 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 5/14/2021. Read SEC document |
| June 24, 2021 Filed Jun 25, 2021 22:15 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionCommon Stock | 1,500 | $6.59 | $9,885.00 |
DisclosureSEC source: 0000950103-21-009417 · dp153299_4-francis.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David and Laura Francis Joint Rev Trust Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 5/14/2021. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 19:29 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,700 | $0.00 Strike: $6.59 | $0.00 |
DisclosureSEC source: 0000950103-21-008900 · dp152751_4-francis.xml · derivative · entry 4 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,890 Underlying: Common Stock · 2,700 shares Expires 2029-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 5/14/2021. F2 · derivative.exercise_date: 1/36th of the shares subject to the option shall vest monthly from 1/3/19. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 19:29 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | SaleCommon Stock | 2,700 | $186.01 | $502,227.00 |
DisclosureSEC source: 0000950103-21-008900 · dp152751_4-francis.xml · nonDerivative · entry 2 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David and Laura Francis Joint Rev Trust Disclosed balance after: 0 F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 5/14/2021. Read SEC document |
| June 14, 2021 Filed Jun 16, 2021 19:29 UTC | Shockwave Medical, Inc. SWAV · Entity 90374 | Exercise / conversionCommon Stock | 2,700 | $6.59 | $17,793.00 |
DisclosureSEC source: 0000950103-21-008900 · dp152751_4-francis.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · David and Laura Francis Joint Rev Trust Disclosed balance after: 2,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: All transactions reported here were effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person on 5/14/2021. Read SEC document |
| May 17, 2021 Filed May 19, 2021 21:13 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 621 | $31.40 | $19,500.39 |
DisclosureSEC source: 0001562180-21-003604 · primarydocument.xml · nonDerivative · entry 4 FRANCIS LAURA · CIK 0001218802 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,177 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 1,442 shares acquired under the SI-BONE, Inc. 2018 Employee Stock Purchase Plan on May 17, 2021. F3 · balance_after: Includes 139,234 shares issuable on settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| May 17, 2021 Filed May 19, 2021 21:13 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,677 | $31.40 | $52,660.48 |
DisclosureSEC source: 0001562180-21-003604 · primarydocument.xml · nonDerivative · entry 3 FRANCIS LAURA · CIK 0001218802 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,356 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| May 17, 2021 Filed May 19, 2021 21:13 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,529 | $31.40 | $48,013.05 |
DisclosureSEC source: 0001562180-21-003604 · primarydocument.xml · nonDerivative · entry 2 FRANCIS LAURA · CIK 0001218802 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,033 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| May 17, 2021 Filed May 19, 2021 21:13 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,415 | $31.40 | $44,433.26 |
DisclosureSEC source: 0001562180-21-003604 · primarydocument.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,562 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| April 18, 2021 Filed Apr 20, 2021 20:24 UTC | SI-BONE, Inc. SIBN · Entity 2501 | GrantCommon Stock | 32,864 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-002886 · primarydocument.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Director · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 211,977 F1 · shares: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit will be vesting over four years and will be released in quarterly installments commencing on May 15, 2021, subject to the Reporting Person's continued service through each relevant vesting date. F2 · balance_after: Includes 149,792 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 18, 2021 Filed Mar 20, 2021 00:31 UTC | SI-BONE, Inc. SIBN · Entity 2501 | Exercise / conversionStock Option (Right to Buy) · Derivative | 18,358 | $0.00 Strike: $4.32 | $0.00 |
DisclosureSEC source: 0001562180-21-002381 · primarydocument.xml · derivative · entry 3 FRANCIS LAURA · CIK 0001218802 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,392 Underlying: Common Stock · 18,358 shares Expires 2025-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over four years commencing on vesting commencement date, subject to Reporting Person's continued service through each relevant vesting date. Read SEC document |
| March 18, 2021 Filed Mar 20, 2021 00:31 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 18,358 | $33.34 | $612,138.33 |
DisclosureSEC source: 0001562180-21-002381 · primarydocument.xml · nonDerivative · entry 2 FRANCIS LAURA · CIK 0001218802 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,113 F1 · kind: The sale reported on this Form 4 was effected pursuant to a 10b5-1 trading plan. F2 · price: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $30.01 to $33.74, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. F3 · balance_after: Includes 116,928 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 18, 2021 Filed Mar 20, 2021 00:31 UTC | SI-BONE, Inc. SIBN · Entity 2501 | Exercise / conversionCommon Stock | 18,358 | $4.32 | $79,306.56 |
DisclosureSEC source: 0001562180-21-002381 · primarydocument.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,471 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 04, 2021 Filed Mar 8, 2021 21:35 UTC | SI-BONE, Inc. SIBN · Entity 2501 | GrantCommon Stock | 100 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-002060 · primarydocument.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,113 F1 · shares: Reflects shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The shares subject to the restricted stock unit vest in lump sum on May 15, 2022, subject to the Reporting Person's continued service through relevant vesting date. F2 · balance_after: Includes 116,928 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:14 UTC | SI-BONE, Inc. SIBN · Entity 2501 | Exercise / conversionStock Option (Right to Buy) · Derivative | 400 | $0.00 Strike: $4.32 | $0.00 |
DisclosureSEC source: 0001562180-21-001952 · primarydocument.xml · derivative · entry 3 FRANCIS LAURA · CIK 0001218802 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,750 Underlying: Common Stock · 400 shares Expires 2025-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over four years commencing on vesting commencement date, subject to Reporting Person's continued service through each relevant vesting date. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:14 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 400 | $33.04 | $13,214.00 |
DisclosureSEC source: 0001562180-21-001952 · primarydocument.xml · nonDerivative · entry 2 FRANCIS LAURA · CIK 0001218802 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,013 F1 · kind: The sale reported on this Form 4 was effected pursuant to a 10b5-1 trading plan. F2 · price: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $33.00 to $33.10, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. F3 · balance_after: Includes 116,828 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one shares of the Issuer's common stock. Read SEC document |
| March 01, 2021 Filed Mar 4, 2021 01:14 UTC | SI-BONE, Inc. SIBN · Entity 2501 | Exercise / conversionCommon Stock | 400 | $4.32 | $1,728.00 |
DisclosureSEC source: 0001562180-21-001952 · primarydocument.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,413 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 00:11 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 433 | $31.05 | $13,445.60 |
DisclosureSEC source: 0001562180-21-001291 · primarydocument.xml · nonDerivative · entry 2 FRANCIS LAURA · CIK 0001218802 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,013 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F2 · balance_after: Includes 116,828 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 16, 2021 Filed Feb 19, 2021 00:11 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 1,170 | $31.05 | $36,331.07 |
DisclosureSEC source: 0001562180-21-001291 · primarydocument.xml · nonDerivative · entry 1 FRANCIS LAURA · CIK 0001218802 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 179,446 F1 · kind: The sale reported on this Form 4 represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The sale satisfies the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 08, 2021 Filed Feb 9, 2021 22:34 UTC | SI-BONE, Inc. SIBN · Entity 2501 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,839 | $0.00 Strike: $4.32 | $0.00 |
DisclosureSEC source: 0001562180-21-001009 · primarydocument.xml · derivative · entry 6 FRANCIS LAURA · CIK 0001218802 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 111,150 Underlying: Common Stock · 9,839 shares Expires 2025-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The shares subject to the option vest in equal monthly installments over four years commencing on vesting commencement date, subject to Reporting Person's continued service through each relevant vesting date. Read SEC document |
| February 08, 2021 Filed Feb 9, 2021 22:34 UTC | SI-BONE, Inc. SIBN · Entity 2501 | SaleCommon Stock | 9,839 | $33.10 | $325,718.13 |
DisclosureSEC source: 0001562180-21-001009 · primarydocument.xml · nonDerivative · entry 4 FRANCIS LAURA · CIK 0001218802 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,616 F1 · kind: The sale reported on this Form 4 was effected pursuant to a 10b5-1 trading plan. F3 · price: The price reported in column 4 is a weighted-average price. The shares were sold in multiple transactions ranging from $33.00 to $33.34, inclusive. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in these footnotes. F4 · balance_after: Includes 121,456 shares issuable on the settlement of restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| February 08, 2021 Filed Feb 9, 2021 22:34 UTC | SI-BONE, Inc. SIBN · Entity 2501 | Exercise / conversionCommon Stock | 9,839 | $4.32 | $42,504.48 |
DisclosureSEC source: 0001562180-21-001009 · primarydocument.xml · nonDerivative · entry 3 FRANCIS LAURA · CIK 0001218802 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,455 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.